Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY25 results · Jan–Mar 2025
Marksans Pharma reported revenue from operations of ₹70.85 crore (down 87.3% from Q4 FY24) and net profit of ₹9.07 crore (down 88.3% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 70.85 | 560.01 | −87.3% | 681.85 | −89.6% |
| Other income | 1.65 | 16.53 | −90.0% | 27.85 | −94.1% |
| Total income | 72.50 | 576.54 | −87.4% | 709.70 | −89.8% |
| Profit before tax | 11.61 | 100.28 | −88.4% | 143.26 | −91.9% |
| Net profit for the period | 9.07 | 77.64 | −88.3% | 105.07 | −91.4% |
| EPS, basic (₹) | 2.00 | 1.73 | not comparable | 2.31 | not comparable |
| Net margin (%) | 12.8 | 13.9 | 15.4 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 299.36 | 225.20 | +32.9% | 311.87 | −4.0% |
| Other income | 7.82 | 12.19 | −35.9% | 22.51 | −65.3% |
| Total income | 307.17 | 237.39 | +29.4% | 334.37 | −8.1% |
| Profit before tax | 49.90 | 38.40 | +30.0% | 74.72 | −33.2% |
| Net profit for the period | 37.59 | 32.99 | +13.9% | 55.46 | −32.2% |
| EPS, basic (₹) | 0.83 | 0.73 | +13.7% | 1.22 | −32.0% |
| Net margin (%) | 12.6 | 14.7 | 17.8 |
Consolidated
- Filed with BSE
- 28 May 2025, 16:06 IST
- Board meeting
- 19 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 May 2025, 16:06 IST
- Board meeting
- 19 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE